Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05568680 · ClinicalTrials.gov registry record · Phase 1
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
A Phase 1 study of Ovarian Cancer and Mesothelioma, Malignant, sponsored by Verismo Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 4
- Study locations
NCT05568680: Recruiting Phase 1 study of Ovarian Cancer and Mesothelioma, Malignant, sponsored by Verismo Therapeutics.
NCT05568680 is a Phase 1 study of Ovarian Cancer and Mesothelioma, Malignant that is actively recruiting participants, run by Verismo Therapeutics. The registered enrollment target is 42 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (94% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05568680, a Phase 1 study of Ovarian Cancer and Mesothelioma, Malignant, is actively recruiting participants, sponsored by Verismo Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 4
- Study locations
Study Summary
This first-in-human (FIH) trial is designed to assess the safety, feasibility, and potential activity of a single intravenous (IV) dose of SynKIR-110 administered to subjects with mesothelin-expressing advanced ovarian cancer, mesothelioma, and cholangiocarcinoma.
Primary Outcome
* The incidence, frequency, and severity of TEAEs, incidence of AEs related to native mesothelin-expressing tissues, Incidence of CRS and/or neurologic toxicity * Frequency of subjects who pass screening to enrollment but do not receive SynKIR-110
Conditions Studied
Interventions
- BIOLOGICAL SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR
Study Locations (4)
Kansas
- University of Kansas Cancer Center - Westwood
Pennsylvania
- University of Pennsylvania - Philadelphia
Texas
- MD Anderson Cancer Center - Houston
Wisconsin
- University of Wisconsin Carbone Cancer Center - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2023-03-30 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
What NCT05568680 shows while recruiting
NCT05568680 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (94% lower).
The record links to 3 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR is the first listed.
NCT05568680 reports a single indexed study location in Kansas, Pennsylvania, Texas.
Frequently Asked Questions
What is clinical trial NCT05568680 about?
NCT05568680 is a clinical study titled "SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma". This first-in-human (FIH) trial is designed to assess the safety, feasibility, and potential activity of a single intravenous (IV) dose of SynKIR-110 administered to subjects with mesothelin-expressing advanced ovarian cancer, mesothelioma, and cholangiocarcinoma.
What is the current status of trial NCT05568680?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2023-03-30. Estimated completion is 2027-12.
What conditions does trial NCT05568680 study?
This clinical trial studies the following conditions: Ovarian Cancer, Mesothelioma, Malignant, Cholangiocarcinoma Recurrent.
What interventions are being tested in trial NCT05568680?
The interventions under investigation include: SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR (BIOLOGICAL).
Who is sponsoring clinical trial NCT05568680?
This trial is sponsored by Verismo Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05568680 being conducted?
This trial has 4 study locations across Kansas, Pennsylvania, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05568680's enrollment target sits among peer trials
42 224th of 322 higher than 97 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI